Oct. 6 at 1:49 PM
Barclays⬆️the PT on
$CYTK to
$82 from
$71 and reiterated at an Overweight rating.
$BMY $EWTX
Barclays said in its note: Ahead of aficamten Ph3 ACACIA data (1H26, likely March/April) in non-obstructive hypertrophic cardiomyopathy (nHCM), we spoke with 2 KOLs and conducted a deep dive on historical clinical data and statistical analysis.
We see a high prob for a positive outcome for dual primary endpoints KCCQ-CSS (>75%) and pVO2 (>55%).
We expect aficamten to become the first approved drug in nHCM and continue to see a high probability of on time (PDUFA Dec 26) approval in oHCM with a differentiated label.
Based on our KOL feedback, we believe aficamten with superior safety profile (therefore operational ease of use) would become the preferred therapy in oHCM/nHCM. Reiterate OW and increase our PT to
$82.
